ROIV - Roivant Sciences Ltd

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Roivant Sciences GAAP EPS of $6.03 beats by $5.54, revenue of $37.14M beats by $7.32M
• Roivant Sciences Q3 2024 Earnings Preview
• Arbutus Biopharma gains after Markman hearing on Thursday in Moderna dispute
• Vivek Ramaswamy offloads $33M Roivant stock
• Bank of America more favorable on SMID-cap biotechs into 2024
• Immunovant stock jumps 9% on positive data for Graves' disease drug
• Roivant slides on failed Phase 2 study for lupus drug candidate
• Biggest stock movers today: Roku, Foot Locker, Shopify and more
• Roivant Sciences GAAP EPS of -$0.40 misses by $0.09, revenue of $37.1M beats by $9.98M
• Roivant Sciences Q2 2024 Earnings Preview
• Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more
• Roche to acquire Telavant for $7.1B, adds new bowel disease therapy to pipeline
• Roivant unit appoints Vincent Hennemand as CEO
• Roivant Sciences COO Eric Venker sells ~440.8K
• Roivant Sciences files for $1.5B mixed shelf
• Immunovant to raise $450M from public offering and private placement
• Immunovant stock rallies for second day, fueled by public offering, drug data
• Immunovant drives OmniAb higher after data update; argenx slips
• Immunovant climbs 102% on Phase 1 data for autoimmune drug (updated)
• Roivant Sciences GAAP EPS of -$0.38 misses by $0.07, revenue of $21.62M misses by $2.87M